Skip to main content
OSTEOPORE LIMITED logo

OSTEOPORE LIMITED — Investor Relations & Filings

Ticker · OSX ISIN · AU0000053324 ASX Manufacturing
Open in API
Filings indexed 488 across all filing types
Latest filing 2024-04-22 Regulatory Filings
Country AU Australia
Listing ASX OSX

About OSTEOPORE LIMITED

https://osteopore.com

Osteopore Limited specializes in the design and manufacture of 3D-printed bioresorbable implants. The company utilizes a patented 3D printing process to create scaffolds from bioresorbable polymers, such as polycaprolactone, designed to mimic the natural microstructure of bone. These implants, including the Osteoplug, Osteomesh, and Osteostrip product lines, are applied in neurosurgical, craniofacial, and orthopedic procedures to facilitate bone healing and tissue regeneration. The scaffolds provide a temporary structural framework that supports the body's natural healing process before being gradually absorbed and replaced by the patient's own bone tissue. This technology aims to reduce long-term complications associated with permanent foreign implants by promoting natural tissue integration and restoration across various clinical applications.

Recent filings

Filing Released Lang Actions
First-in-human clinical trials begin in Singapore 3 pages 355.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 23 April 2024 about the commencement of first-in-human clinical trials by Osteopore Limited. It details the start of clinical trials, the technology involved, and the company's background. There are no financial statements, regulatory certifications, or detailed financial data. The document is an announcement of a clinical trial commencement, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best as a general regulatory announcement about company activities and developments, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other categories.
2024-04-22 English
Pause in Trading 1 page 118.7KB
Regulatory Filings Classification · 95% confidence The document is a brief market release announcing a temporary pause in trading of the company's securities. It is very short (341 characters) and does not contain any financial data, report content, or detailed information. It is an official regulatory announcement related to trading status, not a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-04-22 English
Trading Halt 2 pages 798.4KB
Regulatory Filings Classification · 100% confidence The document is a market announcement from Osteopore Limited regarding a trading halt request. It references ASX Listing Rule 17.1 and states that the trading halt is pending the release of an announcement related to an ASX Price and Volume Query. The document is short (1985 characters) and does not contain any financial data, report content, or detailed analysis. It is an official regulatory announcement about trading status rather than a financial report or detailed disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and compliance documents that do not fit other specific categories.
2024-04-22 English
Response to ASX Price and Volume Query 3 pages 925.6KB
Regulatory Filings Classification · 95% confidence The document is a formal response letter from Osteopore Limited to the ASX Compliance regarding a Price and Volume Query. It addresses questions about unusual trading activity and confirms compliance with listing rules. The content is a regulatory communication related to market disclosure and compliance, not a financial report, earnings release, or other detailed corporate filing. It does not contain financial statements, management discussion, or audit information. The document is a regulatory announcement responding to a market query, fitting the category of Regulatory Filings (RNS).
2024-04-22 English
Annual Report to Shareholders 70 pages 2.0MB
Annual Report Classification · 100% confidence The document is titled 'Consolidated Annual Report For the year ended 31 December 2023' for Osteopore Limited and its controlled entities. It contains detailed sections typical of an annual report, including a letter from the chairman, directors' report, auditor's independence declaration, consolidated financial statements (profit or loss, financial position, changes in equity, cash flows), notes to the financial statements, directors' declaration, and independent auditor's report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of comprehensive financial data and management discussion confirms it is the official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-15 English
Appendix 4G and Corporate Governance Statement 21 pages 615.2KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a detailed key to corporate governance disclosures, indicating compliance with ASX Corporate Governance Council recommendations for the financial year ended 31 December 2023. The document explicitly states it is not a substitute for the corporate governance statement but serves as a verification tool alongside the annual report. It includes references to where governance disclosures can be found (annual report pages or website URLs) but does not itself contain the full corporate governance statement or detailed financial data. The document is a regulatory filing required to be lodged with ASX alongside the annual report but is not the annual report itself. It is a compliance and governance disclosure document, fitting best under Regulatory Filings (RNS) as it does not contain full financial statements or detailed management discussion but is a formal regulatory compliance document related to governance disclosures.
2024-04-15 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.